Literature DB >> 29705703

Esculetin inhibits oxidative stress and apoptosis in H9c2 cardiomyocytes following hypoxia/reoxygenation injury.

Ya He1, Chen Li2, Qiaoya Ma2, Songsheng Chen2.   

Abstract

Esculetin (6,7-dihydroxycoumarin), a natural coumarin compound extracted from natural plants, was reported to be involved in ischemia/reperfusion (I/R) injury. However, the role of esculetin in myocardial I/R injury remains unclear. This study was designed to investigate the protective effects of esculetin on cardiomyocytes induced by hypoxia/reoxygenation (H/R), and explore the underlying mechanisms. Our results showed that esculetin improved the cell viability and decreased lactate dehydrogenase (LDH) release in H/R-stimulated H9c2 cells. In addition, esculetin significantly suppressed oxidative stress and apoptosis in H9c2 cells exposed to H/R treatment. Exploration of the underlying mechanisms of its action indicated that esculetin enhanced the activation of JAK2/STAT3 pathway in H/R-stimulated H9c2 cells. Taken together, these findings indicated that esculetin inhibits oxidative stress and apoptosis in H9c2 cardiomyocytes following H/R injury through the activation of JAK2/STAT3 pathway.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Apoptosis; Esculetin; Myocardial I/R injury; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 29705703     DOI: 10.1016/j.bbrc.2018.04.195

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  [Role of mitochondrial permeability transition pore in mediating the inhibitory effect of gastrodin on oxidative stress in cardiac myocytes in vitro].

Authors:  Xuechao Han; Jingman Xu; Sen Xu; Yahan Sun; Mali He; Xiaodong Li; Xinyu Li; Jiayi Pi; Rui Yu; Wei Tian
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use.

Authors:  Anik Boudreau; Allison J Richard; Innocence Harvey; Jacqueline M Stephens
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-08       Impact factor: 5.555

Review 3.  Promising Therapeutic Candidate for Myocardial Ischemia/Reperfusion Injury: What Are the Possible Mechanisms and Roles of Phytochemicals?

Authors:  Cong Chen; Lin-Tong Yu; Bai-Ru Cheng; Jiang-Lin Xu; Yun Cai; Jia-Lin Jin; Ru-Li Feng; Long Xie; Xin-Yan Qu; Dong Li; Jing Liu; Yan Li; Xiao-Yun Cui; Jin-Jin Lu; Kun Zhou; Qian Lin; Jie Wan
Journal:  Front Cardiovasc Med       Date:  2022-02-17

4.  ALDOA protects cardiomyocytes against H/R-induced apoptosis and oxidative stress by regulating the VEGF/Notch 1/Jagged 1 pathway.

Authors:  Gaiying Luo; Rui Wang; Hui Zhou; Xiaoling Liu
Journal:  Mol Cell Biochem       Date:  2020-10-21       Impact factor: 3.396

5.  Exploring cardioprotective potential of esculetin against isoproterenol induced myocardial toxicity in rats: in vivo and in vitro evidence.

Authors:  Chitikela P Pullaiah; Vinod K Nelson; Sushma Rayapu; Narasimha Kumar G V; Thyagaraju Kedam
Journal:  BMC Pharmacol Toxicol       Date:  2021-07-15       Impact factor: 2.483

6.  Esculetin Ameliorates Psoriasis-Like Skin Disease in Mice by Inducing CD4+Foxp3+ Regulatory T Cells.

Authors:  Yuchao Chen; Qunfang Zhang; Huazhen Liu; Chuanjian Lu; Chun-Ling Liang; Feifei Qiu; Ling Han; Zhenhua Dai
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561

7.  Phytochemical Analysis, Antioxidant and Analgesic Activities of Incarvillea compacta Maxim from the Tibetan Plateau.

Authors:  Jiajia Guo; Dan Zhang; Chao Yu; Ling Yao; Zhuo Chen; Yanduo Tao; Weiguo Cao
Journal:  Molecules       Date:  2019-04-30       Impact factor: 4.411

8.  Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis.

Authors:  Yiming Wang; Weikaixin Kong; Liang Wang; Tianyu Zhang; Boyue Huang; Jia Meng; Baoxue Yang; Zhengwei Xie; Hong Zhou
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.